Table 1 Details of clinical studies
Author and year | Number of patients | Age at presentation/ mean (±SD)/median (range) | Duration of nonoperative treatment (pre-procedure) | Mechanical axis evaluated preoperatively (Y/N) | Bone substitute material used | Postoperative regimen Weight- bearing | Duration of follow up (months) Mean (±SD)/median (range) | Outcome measures | Complications (number) |
|---|---|---|---|---|---|---|---|---|---|
Conway et al. [20] 2019 | 1 | 54 | NR | N | AccuFill® | Toe-touch | 24 | VAS | Increased pain |
Bonadio et al. [12] 2017 | 5 | 67.7(±9.67) | 3 | Y | Graftys HBS® | Full | 6 (±NR) | KOOS VAS | Graft extravasation (1) |
Byrd et al. [21] 2017 | 133 | 57 (38–84) | NR | N | AccuFill® | NR | 32.1 (24–43) | VAS | NR |
Cohen et al. [11] 2016 | 66 | 55.9 (35–76) | 2 | Y | AccuFill® | As tolerated + crutches | 24 (NR) | VAS IKDC | Persistent drainage (1) Deep vein thrombosis (1) |
Chatterjee et al. [17] 2015 | 22 | 53.5 (38–70) | 3 | Y | AccuFill® | Partial (2/52) | 12 (6–24) | KOOS T-L | NR |
Nevalainen et al. [7] 2015 | 2 | 42 58 | 8 NR | N N | AccuFill® AccuFill® | NR NR | 6 14 | NR NR | NR NR |
Farr et al. [13] 2013 | 59 | 55.6 (35–76) | 6 | Y | AccuFill® | As tolerated + crutches | 14.7 (±NR) | VAS IKDC SF12 | Extravasation (N/R) Significant pain treated with nerve block (NR) |
Davis et al. [22] 2015 | 50 | 55 (36–82) | NR | NR | NR | NR | 14.6 (12.9–25.1) | VAS | NR |